Brensocatib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Brensocatib
- Molecular weight
- 420.47
- Structure (SMILES)
- Cn1c(=O)oc2ccc(-c3ccc(C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)cc3)cc21
- azd 7986
- AZD 7986
- Azd-7986
- AZD-7986
- azd7986
- Azd7986
- AZD7986
- brensocatib
- Brensocatib
- brensocatib [INN]
- BRENSOCATIB [USAN]
- Brensocatib [WHO-DD]
- Brensocatib 10 mg
- Brensocatib 25 mg
- brensocatib inn
- Brensocatib Oral Solution
- Brensocatib Oral Tablet
- brensocatib usan
- brensocatib who dd
- ins 1007
- INS-1007
- ins1007
- INS1007
- ATC classification codes
- R03
- CAS registry numbers
- 1802148-05-5
- ChEMBL ID
- CHEMBL3900409
- InChIKey
- AEXFXNFMSAAELR-RXVVDRJESA-N
- PubChem compound IDs
- 118253852
- RxNorm IDs (RxCUI)
- 2721880
- FDA ingredient codes (UNII)
- 25CG88L0BB
- Status
- Authorised
- Status date
- 18 Nov 2025
- Authorisation date
- 18 Nov 2025
- Approved indications
- Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.
- Product number
- EMEA/H/C/005820
- Authorisation holder
- Insmed Netherlands B.V.
- Priority medicines scheme
- Yes
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- Yes
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Bronchiectasis
- Lung Diseases
European medicines record
- Patents
- 14
- Designations
- 5
- Earliest recorded loss of exclusivity
- 21 Feb 2040
- First in class
- No
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- brensocatib
- Type
- Synthetic organic
- Drug name stem
- -catib
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- cathepsin C
- Gene symbol
- CTSC
- Protein identifier
- P53634
- Median affinity
- 8.4
- Affinity units
- pIC50
- Primary target
- Yes
- Mechanism
- Dipeptidyl peptidase I inhibitor
- Action type
- Inhibitor
- Target
- Dipeptidyl peptidase 1
- Protein identifier
- P53634
Open Targets mechanisms
- Mechanism
- Dipeptidyl peptidase I inhibitor
- Action type
- Inhibitor
- Target
- Dipeptidyl peptidase 1
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Bronchiectasis
- Highest recorded phase
- 3
- Condition identifier
- HP:0002110
- Subject identifier
- D001987
- Condition
- Bronchiectasis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004822
- Subject identifier
- D001987
- Condition
- Cystic Fibrosis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0009061
- Subject identifier
- D003550
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003818
- Condition identifier
- EFO_1000710
- Highest recorded phase
- 2
- Condition identifier
- EFO_1002030
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004822
- Condition identifier
- MONDO_0004822
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005275
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0006502
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006559
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0009061
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT03218917
- NCT04594369
- NCT04817332
- NCT05090904
- NCT05517525
- NCT05673603
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 2
- Polar surface area
- 109.29
- Calculated partition coefficient (ALogP)
- 1.73
- Calculated partition coefficient (XLogP)
- 2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 31
- Molecular formula
- C23H24N4O4
- Monoisotopic mass
- 420.17975526
- Natural product
- No
- 71558-001
- 71558-002
- Recorded assays
- 108
- Active assays
- 37
- Confirmatory
- Other
These details could not be displayed.
Related records
Trials (18)
- A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects
- A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment
- A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants
- A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
- A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
- A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants
- A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants
- A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants
- A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
- A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
- A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
- A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
- A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants
- An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis
- Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
- Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study
- STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19
In development for (6)
- Bronchiectasis Phase 3
- COVID-19 Phase 3
- Cystic fibrosis Phase 2
- Hidradenitis suppurativa Phase 2
- Kidney disorder Phase 1
- Liver disorder Phase 1
Other linked conditions (1)
Targets (1)
- CTSC Dipeptidyl peptidase I inhibitor